Maccura Biotechnology Co Ltd (300463) - Net Assets
Based on the latest financial reports, Maccura Biotechnology Co Ltd (300463) has net assets worth CN¥6.38 Billion CNY (≈ $933.50 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.99 Billion ≈ $1.17 Billion USD) and total liabilities (CN¥1.61 Billion ≈ $235.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Maccura Biotechnology Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.38 Billion |
| % of Total Assets | 79.85% |
| Annual Growth Rate | 26.2% |
| 5-Year Change | 60.37% |
| 10-Year Change | 221.11% |
| Growth Volatility | 38.0 |
Maccura Biotechnology Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Maccura Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Maccura Biotechnology Co Ltd (300463) total assets for the complete picture of this company's asset base.
Annual Net Assets for Maccura Biotechnology Co Ltd (2011–2024)
The table below shows the annual net assets of Maccura Biotechnology Co Ltd from 2011 to 2024. For live valuation and market cap data, see 300463 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.42 Billion ≈ $939.98 Million |
-2.84% |
| 2023-12-31 | CN¥6.61 Billion ≈ $967.46 Million |
+1.25% |
| 2022-12-31 | CN¥6.53 Billion ≈ $955.50 Million |
+43.77% |
| 2021-12-31 | CN¥4.54 Billion ≈ $664.60 Million |
+13.39% |
| 2020-12-31 | CN¥4.01 Billion ≈ $586.12 Million |
+20.37% |
| 2019-12-31 | CN¥3.33 Billion ≈ $486.94 Million |
+16.15% |
| 2018-12-31 | CN¥2.86 Billion ≈ $419.24 Million |
+9.64% |
| 2017-12-31 | CN¥2.61 Billion ≈ $382.37 Million |
+14.44% |
| 2016-12-31 | CN¥2.28 Billion ≈ $334.12 Million |
+14.14% |
| 2015-12-31 | CN¥2.00 Billion ≈ $292.73 Million |
+152.57% |
| 2014-12-31 | CN¥792.05 Million ≈ $115.90 Million |
+31.03% |
| 2013-12-31 | CN¥604.48 Million ≈ $88.46 Million |
+36.46% |
| 2012-12-31 | CN¥442.98 Million ≈ $64.82 Million |
+42.09% |
| 2011-12-31 | CN¥311.77 Million ≈ $45.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Maccura Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1618.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.87 Billion | 60.81% |
| Common Stock | CN¥612.47 Million | 9.62% |
| Other Comprehensive Income | CN¥322.67 Million | 5.07% |
| Other Components | CN¥1.56 Billion | 24.51% |
| Total Equity | CN¥6.37 Billion | 100.00% |
Maccura Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Maccura Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guoguang Electric Co Ltd
SHE:002045
|
$928.45 Million |
|
GlaxoSmithKline PLC
LSE:GSK
|
$929.05 Million |
|
Banco da Amazônia S.A
SA:BAZA3
|
$929.25 Million |
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
$929.30 Million |
|
Asiainfo Security Technologies Corp. A
SHG:688225
|
$927.76 Million |
|
Universal Insurance Holdings Inc
NYSE:UVE
|
$927.72 Million |
|
Pharming Group NV
AS:PHARM
|
$927.29 Million |
|
Zhejiang Cayi Vacuum Container Co. Ltd.
SHE:301004
|
$927.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maccura Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,384,825,270 to 6,369,056,728, a change of -15,768,542 (-0.2%).
- Net income of 126,805,277 contributed positively to equity growth.
- Dividend payments of 115,190,048 reduced retained earnings.
- Share repurchases of 24,563,040 reduced equity.
- Other comprehensive income increased equity by 322,667,679.
- Other factors decreased equity by 325,488,410.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥126.81 Million | +1.99% |
| Dividends Paid | CN¥115.19 Million | -1.81% |
| Share Repurchases | CN¥24.56 Million | -0.39% |
| Other Comprehensive Income | CN¥322.67 Million | +5.07% |
| Other Changes | CN¥-325.49 Million | -5.11% |
| Total Change | CN¥- | -0.25% |
Book Value vs Market Value Analysis
This analysis compares Maccura Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 15.01x to 1.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.70 | CN¥10.49 | x |
| 2012-12-31 | CN¥1.00 | CN¥10.49 | x |
| 2013-12-31 | CN¥1.36 | CN¥10.49 | x |
| 2014-12-31 | CN¥1.77 | CN¥10.49 | x |
| 2015-12-31 | CN¥3.58 | CN¥10.49 | x |
| 2016-12-31 | CN¥4.03 | CN¥10.49 | x |
| 2017-12-31 | CN¥4.48 | CN¥10.49 | x |
| 2018-12-31 | CN¥4.87 | CN¥10.49 | x |
| 2019-12-31 | CN¥5.61 | CN¥10.49 | x |
| 2020-12-31 | CN¥6.81 | CN¥10.49 | x |
| 2021-12-31 | CN¥7.72 | CN¥10.49 | x |
| 2022-12-31 | CN¥10.35 | CN¥10.49 | x |
| 2023-12-31 | CN¥10.42 | CN¥10.49 | x |
| 2024-12-31 | CN¥10.40 | CN¥10.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maccura Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.98%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.25x
- Recent ROE (1.99%) is below the historical average (19.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 38.62% | 23.10% | 1.03x | 1.62x | CN¥89.24 Million |
| 2012 | 35.71% | 26.10% | 0.96x | 1.42x | CN¥113.91 Million |
| 2013 | 31.95% | 24.78% | 0.93x | 1.38x | CN¥132.71 Million |
| 2014 | 28.56% | 24.20% | 0.77x | 1.54x | CN¥147.01 Million |
| 2015 | 12.58% | 23.57% | 0.45x | 1.19x | CN¥51.53 Million |
| 2016 | 13.91% | 20.96% | 0.55x | 1.20x | CN¥87.68 Million |
| 2017 | 14.96% | 18.99% | 0.55x | 1.43x | CN¥124.06 Million |
| 2018 | 16.51% | 16.57% | 0.59x | 1.69x | CN¥175.40 Million |
| 2019 | 16.80% | 16.30% | 0.59x | 1.76x | CN¥212.62 Million |
| 2020 | 20.91% | 21.43% | 0.58x | 1.68x | CN¥414.25 Million |
| 2021 | 22.25% | 24.03% | 0.61x | 1.53x | CN¥526.75 Million |
| 2022 | 11.25% | 19.63% | 0.44x | 1.30x | CN¥78.85 Million |
| 2023 | 4.90% | 10.80% | 0.36x | 1.27x | CN¥-325.86 Million |
| 2024 | 1.99% | 4.98% | 0.32x | 1.25x | CN¥-510.10 Million |
Industry Comparison
This section compares Maccura Biotechnology Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $4,845,852,294
- Average return on equity (ROE) among peers: 20.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maccura Biotechnology Co Ltd (300463) | CN¥6.38 Billion | 38.62% | 0.25x | $928.17 Million |
| Berry Genomics Co Ltd (000710) | $2.33 Billion | -10.83% | 0.37x | $516.80 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.77 Billion |
| Hangzhou Tigermed Consulting (300347) | $24.45 Billion | 8.28% | 0.21x | $5.96 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $3.27 Billion | 11.90% | 0.41x | $1.09 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.52 Billion | 7.88% | 0.42x | $567.44 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $501.67 Million | 15.17% | 0.15x | $573.30 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.44 Billion |
| Amoy Diagnostics Co Ltd (300685) | $756.74 Million | 16.75% | 0.08x | $1.16 Billion |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $130.79 Million | 64.49% | 1.52x | $605.42 Million |
About Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more